The smart insulin pens market size has grown strongly in recent years. It will grow from $0.11 billion in 2024 to $0.12 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increase in diabetes prevalence, strong economic growth in emerging markets, increased geriatric population, increased healthcare expenditure and public health insurance reforms.
The smart insulin pens market size is expected to see strong growth in the next few years. It will grow to $0.15 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to an increase in disease burden, government initiatives and technological enhancements. Major trends in the forecast period include collaborating with technology companies, smart insulin delivery devices, new types of insulin delivery, integrating internet of things and increasing mergers and acquisitions.
Achieving an accurate dose of insulin is more feasible with an insulin pen compared to a vial or syringe. For scenarios such as children requiring insulin during school hours and visually impaired diabetic patients, the insulin pen allows for pre-setting an accurate dose over the dosage dial, ensuring precise delivery at the time of injection. Pediatric-friendly insulin pens such as Novo Nordisk's Echo Plus enable half-unit dosing, with a maximum of 30 units. Other options such as Lilly's HumaPen Luxura HD allow insulin delivery in half-unit increments, and Novo Nordisk's NovoPen Junior offers highly accurate insulin doses, finely adjusting even in half-unit increments. The precision in dose adjustments and delivery offered by smart insulin pens can prevent both over-dosing and under-dosing, contributing to the expected increase in demand for smart insulin pens and driving market growth.
The rising global diabetic population is expected to significantly boost the growth of the smart insulin pen market in the coming years. The diabetic population consists of individuals diagnosed with diabetes, a chronic condition characterized by elevated blood glucose levels. Smart insulin pens enhance diabetes management by providing precise insulin dosage tracking, reminders, and data integration, which improves treatment adherence and overall glycemic control for those with diabetes. For example, in July 2022, the International Diabetes Federation, a Belgium-based non-profit organization, reported that approximately 537 million adults worldwide were living with diabetes in 2022. This figure is projected to rise to 643 million by 2030 and further to 783 million by 2045. Thus, the increasing global diabetic population is driving the growth of the smart insulin pen market.
The next generation of smart insulin pens extends well beyond simple memory storage, they assist in calculating personalized doses, continuously track glucose levels, and connect to smartphone apps for data visualization. In April 2022, Eli Lilly and Company, a U.S.-based multinational pharmaceutical firm, announced the Tempo® Personalized Diabetes Management Platform. This comprehensive system is designed to improve diabetes self-management for adults with type 1 and type 2 diabetes. The Tempo Smart Button is a reusable device that attaches to the Tempo Pen, capturing and transferring insulin dosing data, while the TempoSmart™ App logs these doses and offers personalized education and medication reminders.
Major companies in the smart insulin pens market are strategically focusing on introducing user-friendly insulin pens, such as the NovoPen 6 and the NovoPen Echo Plus, to optimize revenue in the market. These self-injection pens automatically record insulin dosing information for each injection. For instance, in March 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched the first smart insulin pens - NovoPen 6 and NovoPen Echo Plus. These pens record details such as the timing and quantity of insulin administered, uploading the data to an app via near-field communication (NFC). The pens facilitate the transfer of insulin dosing information to a patient's preferred diabetes app, allowing data sharing with healthcare providers. They are compatible with smartphones, tablets, personal computers, blood glucose monitors, or other NFC-supported devices.
In October 2023, Novo Nordisk A/S acquired Biocorp, a France-based medical device company specializing in the development and manufacturing of drug-delivery systems and medical devices, for $164.5 million. This acquisition is expected to enable Novo Nordisk to further invest in Biocorp's device development and expedite its ambitions within devices and delivery solutions.
Major companies operating in the smart insulin pens market include Companion Medical, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Emperra GmbH E-Health Technologies, Diamesco Co. Ltd., Digital Medics Pvt Ltd., Bigfoot Biomedical, Diabnext, Insulet Corporation, Jiangsu Delfu Medical Device Co. Ltd., Sanofi India, Becton Dickinson, Biocon Ltd, Mehar healthcare, Johnson & Johnson, Covidien Healthcare, Philips Healthcare India, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell medical equipment & supply Co, Terumo, NIPRO, Olympus Medical Systems, Nihon Koden, Medtronic PLC, Ypsomed Holding AG, Berlin-Chemie AG, Patients Pending Ltd, Dexcom, Insujet, Eli Lilly., Abbott Laboratories, Tandem Diabetes Care, Inc.
North America was the largest region in the smart insulin pens market in 2024. Western Europe was the second largest region in the global smart insulin pens market share. The regions covered in the smart insulin pens market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart insulin pens market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Smart insulin pens refer to insulin delivery devices designed to monitor and record dosage information, including volume, time, and type. Additionally, these devices may offer functionalities such as generating reports for sharing with healthcare professionals.
Two primary types of smart insulin pens exist first-generation pens and second-generation pens (equipped with Bluetooth or USB connectivity). Second-generation smart insulin pens incorporate Bluetooth or USB features to facilitate closer monitoring. These pens come in either prefilled or reusable forms and are utilized for the treatment of both type 1 diabetes and type 2 diabetes. Smart insulin pens find application across various end-users, including hospitals and clinics, ambulatory surgical centers, as well as home care settings.
The smart insulin pens market research report is one of a series of new reports that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The smart insulin pens market size is expected to see strong growth in the next few years. It will grow to $0.15 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to an increase in disease burden, government initiatives and technological enhancements. Major trends in the forecast period include collaborating with technology companies, smart insulin delivery devices, new types of insulin delivery, integrating internet of things and increasing mergers and acquisitions.
Achieving an accurate dose of insulin is more feasible with an insulin pen compared to a vial or syringe. For scenarios such as children requiring insulin during school hours and visually impaired diabetic patients, the insulin pen allows for pre-setting an accurate dose over the dosage dial, ensuring precise delivery at the time of injection. Pediatric-friendly insulin pens such as Novo Nordisk's Echo Plus enable half-unit dosing, with a maximum of 30 units. Other options such as Lilly's HumaPen Luxura HD allow insulin delivery in half-unit increments, and Novo Nordisk's NovoPen Junior offers highly accurate insulin doses, finely adjusting even in half-unit increments. The precision in dose adjustments and delivery offered by smart insulin pens can prevent both over-dosing and under-dosing, contributing to the expected increase in demand for smart insulin pens and driving market growth.
The rising global diabetic population is expected to significantly boost the growth of the smart insulin pen market in the coming years. The diabetic population consists of individuals diagnosed with diabetes, a chronic condition characterized by elevated blood glucose levels. Smart insulin pens enhance diabetes management by providing precise insulin dosage tracking, reminders, and data integration, which improves treatment adherence and overall glycemic control for those with diabetes. For example, in July 2022, the International Diabetes Federation, a Belgium-based non-profit organization, reported that approximately 537 million adults worldwide were living with diabetes in 2022. This figure is projected to rise to 643 million by 2030 and further to 783 million by 2045. Thus, the increasing global diabetic population is driving the growth of the smart insulin pen market.
The next generation of smart insulin pens extends well beyond simple memory storage, they assist in calculating personalized doses, continuously track glucose levels, and connect to smartphone apps for data visualization. In April 2022, Eli Lilly and Company, a U.S.-based multinational pharmaceutical firm, announced the Tempo® Personalized Diabetes Management Platform. This comprehensive system is designed to improve diabetes self-management for adults with type 1 and type 2 diabetes. The Tempo Smart Button is a reusable device that attaches to the Tempo Pen, capturing and transferring insulin dosing data, while the TempoSmart™ App logs these doses and offers personalized education and medication reminders.
Major companies in the smart insulin pens market are strategically focusing on introducing user-friendly insulin pens, such as the NovoPen 6 and the NovoPen Echo Plus, to optimize revenue in the market. These self-injection pens automatically record insulin dosing information for each injection. For instance, in March 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched the first smart insulin pens - NovoPen 6 and NovoPen Echo Plus. These pens record details such as the timing and quantity of insulin administered, uploading the data to an app via near-field communication (NFC). The pens facilitate the transfer of insulin dosing information to a patient's preferred diabetes app, allowing data sharing with healthcare providers. They are compatible with smartphones, tablets, personal computers, blood glucose monitors, or other NFC-supported devices.
In October 2023, Novo Nordisk A/S acquired Biocorp, a France-based medical device company specializing in the development and manufacturing of drug-delivery systems and medical devices, for $164.5 million. This acquisition is expected to enable Novo Nordisk to further invest in Biocorp's device development and expedite its ambitions within devices and delivery solutions.
Major companies operating in the smart insulin pens market include Companion Medical, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Emperra GmbH E-Health Technologies, Diamesco Co. Ltd., Digital Medics Pvt Ltd., Bigfoot Biomedical, Diabnext, Insulet Corporation, Jiangsu Delfu Medical Device Co. Ltd., Sanofi India, Becton Dickinson, Biocon Ltd, Mehar healthcare, Johnson & Johnson, Covidien Healthcare, Philips Healthcare India, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell medical equipment & supply Co, Terumo, NIPRO, Olympus Medical Systems, Nihon Koden, Medtronic PLC, Ypsomed Holding AG, Berlin-Chemie AG, Patients Pending Ltd, Dexcom, Insujet, Eli Lilly., Abbott Laboratories, Tandem Diabetes Care, Inc.
North America was the largest region in the smart insulin pens market in 2024. Western Europe was the second largest region in the global smart insulin pens market share. The regions covered in the smart insulin pens market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart insulin pens market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Smart insulin pens refer to insulin delivery devices designed to monitor and record dosage information, including volume, time, and type. Additionally, these devices may offer functionalities such as generating reports for sharing with healthcare professionals.
Two primary types of smart insulin pens exist first-generation pens and second-generation pens (equipped with Bluetooth or USB connectivity). Second-generation smart insulin pens incorporate Bluetooth or USB features to facilitate closer monitoring. These pens come in either prefilled or reusable forms and are utilized for the treatment of both type 1 diabetes and type 2 diabetes. Smart insulin pens find application across various end-users, including hospitals and clinics, ambulatory surgical centers, as well as home care settings.
The smart insulin pens market research report is one of a series of new reports that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Smart Insulin Pens Market Characteristics3. Smart Insulin Pens Market Trends and Strategies4. Smart Insulin Pens Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Smart Insulin Pens Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Smart Insulin Pens Market34. Recent Developments in the Smart Insulin Pens Market
5. Global Smart Insulin Pens Growth Analysis and Strategic Analysis Framework
6. Smart Insulin Pens Market Segmentation
7. Smart Insulin Pens Market Regional and Country Analysis
8. Asia-Pacific Smart Insulin Pens Market
9. China Smart Insulin Pens Market
10. India Smart Insulin Pens Market
11. Japan Smart Insulin Pens Market
12. Australia Smart Insulin Pens Market
13. Indonesia Smart Insulin Pens Market
14. South Korea Smart Insulin Pens Market
15. Western Europe Smart Insulin Pens Market
16. UK Smart Insulin Pens Market
17. Germany Smart Insulin Pens Market
18. France Smart Insulin Pens Market
19. Italy Smart Insulin Pens Market
20. Spain Smart Insulin Pens Market
21. Eastern Europe Smart Insulin Pens Market
22. Russia Smart Insulin Pens Market
23. North America Smart Insulin Pens Market
24. USA Smart Insulin Pens Market
25. Canada Smart Insulin Pens Market
26. South America Smart Insulin Pens Market
27. Brazil Smart Insulin Pens Market
28. Middle East Smart Insulin Pens Market
29. Africa Smart Insulin Pens Market
30. Smart Insulin Pens Market Competitive Landscape and Company Profiles
31. Smart Insulin Pens Market Other Major and Innovative Companies
35. Smart Insulin Pens Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Smart Insulin Pens Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on smart insulin pens market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for smart insulin pens? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The smart insulin pens market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: First Generation Pens, Second Generation Pens2) By Usability: Prefilled, Reusable
3) By Application: Type 1 Diabetes, Type 2 Diabetes
4) By End User: Hospitals & Clinics, Ambulatory Surgical Centres, Home Care Settings
Subsegments:
1) By First Generation Pens: Basic Smart Insulin Pens With Standard Features; Simple Connectivity to Mobile Apps for Tracking and Logging Insulin Doses2) By Second Generation Pens: Advanced Smart Insulin Pens With Enhanced Features; Real-Time Data Sharing With Healthcare Providers and Caregivers; Sophisticated Mobile Applications for Comprehensive Diabetes Management
Key Companies Mentioned: Companion Medical; Novo Nordisk a/S; F. Hoffmann-La Roche AG; Emperra GmbH E-Health Technologies; Diamesco Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Companion Medical
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
- Emperra GmbH E-Health Technologies
- Diamesco Co. Ltd.
- Digital Medics Pvt Ltd.
- Bigfoot Biomedical
- Diabnext
- Insulet Corporation
- Jiangsu Delfu Medical Device Co. Ltd.
- Sanofi India
- Becton Dickinson
- Biocon Ltd
- Mehar healthcare
- Johnson & Johnson
- Covidien Healthcare
- Philips Healthcare India
- Shandong WeiGao Group Medical Polymer Company Limited
- Yuwell medical equipment & supply Co
- Terumo
- NIPRO
- Olympus Medical Systems
- Nihon Koden
- Medtronic PLC
- Ypsomed Holding AG
- Berlin-Chemie AG
- Patients Pending Ltd
- Dexcom
- Insujet
- Eli Lilly.
- Abbott Laboratories
- Tandem Diabetes Care, Inc.
